Alnylam Net Invested Capital vs Short Long Term Debt Analysis

ALNY Stock

USD 143.31 0.40 0.28%

Alnylam Pharmaceuticals financial indicator trend analysis is way more than just evaluating Alnylam Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Alnylam Pharmaceuticals is a good investment. Please check the relationship between Alnylam Pharmaceuticals Net Invested Capital and its Short Long Term Debt accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alnylam Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.

Net Invested Capital vs Short Long Term Debt

Net Invested Capital vs Short Long Term Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Alnylam Pharmaceuticals Net Invested Capital account and Short Long Term Debt. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Alnylam Pharmaceuticals' Net Invested Capital and Short Long Term Debt is 0.8. Overlapping area represents the amount of variation of Net Invested Capital that can explain the historical movement of Short Long Term Debt in the same time period over historical financial statements of Alnylam Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Alnylam Pharmaceuticals' Net Invested Capital and Short Long Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Invested Capital of Alnylam Pharmaceuticals are associated (or correlated) with its Short Long Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Long Term Debt has no effect on the direction of Net Invested Capital i.e., Alnylam Pharmaceuticals' Net Invested Capital and Short Long Term Debt go up and down completely randomly.

Correlation Coefficient

0.8

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Net Invested Capital

The total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents.

Short Long Term Debt

The total of a company’s short-term and long-term borrowings.

Most indicators from Alnylam Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Alnylam Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alnylam Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.At this time, Alnylam Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 7.1 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 0.41 in 2024.

	2021	2022	2023	2024 (projected)
Gross Profit	704.1M	868.6M	1.5B	1.6B
Total Revenue	844.3M	1.0B	1.8B	1.9B

Gross Profit Total Revenue

Alnylam Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Property Plant Equipment	Short Long Term Debt Total	Other Liab	Current Deferred Revenue	Long Term Debt	Other Stockholder Equity
Total Assets		0.93	0.92	-0.1	0.95	0.6	-0.97	0.75	0.64	0.92	-0.53	0.72	0.98	0.78	0.96	0.87	0.32	0.91	0.96	0.99	0.96	0.78	0.7	0.43	0.85	0.98
Other Current Liab	0.93		0.86	-0.44	0.91	0.82	-0.97	0.63	0.51	0.86	-0.7	0.74	0.88	0.59	0.91	0.98	0.36	0.99	0.98	0.92	0.94	0.93	0.67	0.26	0.96	0.9
Total Current Liabilities	0.92	0.86		-0.13	0.96	0.59	-0.89	0.66	0.43	0.94	-0.42	0.58	0.85	0.7	0.91	0.79	0.33	0.86	0.92	0.87	0.92	0.68	0.79	0.7	0.74	0.89
Total Stockholder Equity	-0.1	-0.44	-0.13		-0.17	-0.71	0.26	0.05	0.2	-0.13	0.49	-0.26	0.01	0.29	-0.11	-0.56	-0.23	-0.49	-0.31	-0.08	-0.19	-0.58	-0.2	0.27	-0.56	-0.02
Property Plant And Equipment Net	0.95	0.91	0.96	-0.17		0.64	-0.96	0.77	0.45	0.96	-0.46	0.65	0.88	0.73	0.95	0.85	0.4	0.9	0.96	0.91	0.98	0.73	0.72	0.54	0.82	0.95
Net Debt	0.6	0.82	0.59	-0.71	0.64		-0.71	0.27	0.03	0.59	-0.84	0.67	0.51	0.17	0.67	0.84	0.3	0.81	0.77	0.58	0.7	0.91	0.41	0.05	0.83	0.57
Retained Earnings	-0.97	-0.97	-0.89	0.26	-0.96	-0.71		-0.77	-0.55	-0.9	0.6	-0.76	-0.93	-0.74	-0.95	-0.93	-0.38	-0.96	-0.98	-0.96	-0.98	-0.84	-0.67	-0.33	-0.92	-0.97
Accounts Payable	0.75	0.63	0.66	0.05	0.77	0.27	-0.77		0.4	0.73	-0.07	0.7	0.72	0.84	0.72	0.59	0.35	0.63	0.68	0.72	0.75	0.37	0.56	0.27	0.62	0.79
Cash	0.64	0.51	0.43	0.2	0.45	0.03	-0.55	0.4		0.37	-0.34	0.34	0.75	0.6	0.46	0.47	0.03	0.48	0.47	0.71	0.47	0.44	0.37	0.09	0.48	0.62
Non Current Assets Total	0.92	0.86	0.94	-0.13	0.96	0.59	-0.9	0.73	0.37		-0.38	0.62	0.83	0.72	0.91	0.79	0.35	0.86	0.93	0.85	0.93	0.66	0.62	0.57	0.73	0.9
Non Currrent Assets Other	-0.53	-0.7	-0.42	0.49	-0.46	-0.84	0.6	-0.07	-0.34	-0.38		-0.56	-0.53	-0.15	-0.53	-0.71	-0.14	-0.66	-0.64	-0.57	-0.57	-0.9	-0.23	0.1	-0.71	-0.52
Other Assets	0.72	0.74	0.58	-0.26	0.65	0.67	-0.76	0.7	0.34	0.62	-0.56		0.71	0.55	0.71	0.74	0.18	0.74	0.73	0.73	0.71	0.71	0.48	0.03	0.8	0.73
Cash And Short Term Investments	0.98	0.88	0.85	0.01	0.88	0.51	-0.93	0.72	0.75	0.83	-0.53	0.71		0.8	0.93	0.81	0.24	0.85	0.9	0.99	0.9	0.74	0.68	0.37	0.81	0.97
Common Stock Shares Outstanding	0.78	0.59	0.7	0.29	0.73	0.17	-0.74	0.84	0.6	0.72	-0.15	0.55	0.8		0.72	0.51	0.28	0.57	0.66	0.78	0.72	0.38	0.52	0.46	0.5	0.82
Short Term Investments	0.96	0.91	0.91	-0.11	0.95	0.67	-0.95	0.72	0.46	0.91	-0.53	0.71	0.93	0.72		0.84	0.35	0.89	0.96	0.94	0.96	0.75	0.71	0.45	0.82	0.96
Non Current Liabilities Total	0.87	0.98	0.79	-0.56	0.85	0.84	-0.93	0.59	0.47	0.79	-0.71	0.74	0.81	0.51	0.84		0.37	0.99	0.93	0.86	0.88	0.94	0.62	0.17	0.99	0.83
Other Current Assets	0.32	0.36	0.33	-0.23	0.4	0.3	-0.38	0.35	0.03	0.35	-0.14	0.18	0.24	0.28	0.35	0.37		0.37	0.38	0.3	0.39	0.28	0.32	0.14	0.34	0.32
Total Liab	0.91	0.99	0.86	-0.49	0.9	0.81	-0.96	0.63	0.48	0.86	-0.66	0.74	0.85	0.57	0.89	0.99	0.37		0.97	0.9	0.91	0.92	0.69	0.27	0.97	0.87
Property Plant And Equipment Gross	0.96	0.98	0.92	-0.31	0.96	0.77	-0.98	0.68	0.47	0.93	-0.64	0.73	0.9	0.66	0.96	0.93	0.38	0.97		0.93	0.98	0.86	0.69	0.38	0.9	0.94
Total Current Assets	0.99	0.92	0.87	-0.08	0.91	0.58	-0.96	0.72	0.71	0.85	-0.57	0.73	0.99	0.78	0.94	0.86	0.3	0.9	0.93		0.93	0.79	0.69	0.35	0.86	0.97
Property Plant Equipment	0.96	0.94	0.92	-0.19	0.98	0.7	-0.98	0.75	0.47	0.93	-0.57	0.71	0.9	0.72	0.96	0.88	0.39	0.91	0.98	0.93		0.79	0.67	0.42	0.85	0.97
Short Long Term Debt Total	0.78	0.93	0.68	-0.58	0.73	0.91	-0.84	0.37	0.44	0.66	-0.9	0.71	0.74	0.38	0.75	0.94	0.28	0.92	0.86	0.79	0.79		0.5	0.07	0.93	0.74
Other Liab	0.7	0.67	0.79	-0.2	0.72	0.41	-0.67	0.56	0.37	0.62	-0.23	0.48	0.68	0.52	0.71	0.62	0.32	0.69	0.69	0.69	0.67	0.5		0.54	0.63	0.64
Current Deferred Revenue	0.43	0.26	0.7	0.27	0.54	0.05	-0.33	0.27	0.09	0.57	0.1	0.03	0.37	0.46	0.45	0.17	0.14	0.27	0.38	0.35	0.42	0.07	0.54		0.1	0.41
Long Term Debt	0.85	0.96	0.74	-0.56	0.82	0.83	-0.92	0.62	0.48	0.73	-0.71	0.8	0.81	0.5	0.82	0.99	0.34	0.97	0.9	0.86	0.85	0.93	0.63	0.1		0.81
Other Stockholder Equity	0.98	0.9	0.89	-0.02	0.95	0.57	-0.97	0.79	0.62	0.9	-0.52	0.73	0.97	0.82	0.96	0.83	0.32	0.87	0.94	0.97	0.97	0.74	0.64	0.41	0.81

Click cells to compare fundamentals

Alnylam Pharmaceuticals Account Relationship Matchups

Alnylam Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	2.4B	3.4B	3.6B	3.5B	3.8B	4.0B
Other Current Liab	206.5M	393.8M	494.1M	585.7M	713.0M	748.7M
Total Current Liabilities	956.4M	1.1B	1.2B	767.9M	967.8M	1.0B
Total Stockholder Equity	1.4B	1.0B	588.2M	(158.2M)	(220.6M)	(209.6M)
Property Plant And Equipment Net	646.4M	706.5M	733.6M	738.6M	725.8M	762.1M
Net Debt	(243.4M)	24.6M	177.6M	453.9M	1.9B	2.0B
Retained Earnings	(3.7B)	(4.6B)	(5.4B)	(6.6B)	(7.0B)	(6.7B)
Accounts Payable	49.9M	52.0M	73.4M	98.1M	55.5M	28.9M
Cash	547.2M	496.6M	820.0M	866.4M	812.7M	853.3M
Non Current Assets Total	661.2M	1.2B	774.5M	854.1M	847.2M	889.5M
Non Currrent Assets Other	18.1M	500M	40.9M	115.5M	(3.5B)	(3.4B)
Other Assets	32.9M	40.7M	101.1M	115.5M	132.8M	139.4M
Cash And Short Term Investments	1.5B	1.9B	2.4B	2.2B	2.4B	2.6B
Common Stock Shares Outstanding	109.3M	115.0M	118.5M	121.7M	124.9M	70.4M
Short Term Investments	989.0M	1.4B	1.6B	1.3B	1.6B	1.7B
Liabilities And Stockholders Equity	2.4B	3.4B	3.6B	3.5B	3.8B	4.0B
Non Current Liabilities Total	603.8M	1.3B	1.9B	2.9B	3.1B	3.2B
Other Current Assets	98.4M	90.7M	111.9M	132.9M	126.4M	68.9M
Total Liab	956.4M	2.4B	3.1B	3.7B	4.1B	4.3B
Property Plant And Equipment Gross	425.2M	706.5M	733.6M	738.6M	948.9M	996.3M
Total Current Assets	1.7B	2.2B	2.9B	2.7B	3.0B	3.1B
Accumulated Other Comprehensive Income	(36.5M)	(43.6M)	(33.3M)	(44.7M)	(23.4M)	(22.2M)
Property Plant Equipment	425.2M	465.0M	502.0M	523.5M	602.0M	632.1M
Short Long Term Debt Total	303.8M	521.2M	997.6M	1.3B	2.7B	2.8B
Other Liab	327.7M	352.3M	1.4B	406.4M	467.3M	490.7M
Current Deferred Revenue	396.2M	352.3M	301.8M	42.1M	102.8M	119.3M
Other Stockholder Equity	5.2B	5.6B	6.1B	6.5B	6.8B	7.2B
Short Term Debt	303.8M	329.9M	321.9M	42.0M	96.5M	59.5M
Net Receivables	43.0M	102.4M	198.6M	238.0M	327.8M	344.2M
Common Stock Total Equity	1.1M	1.2M	1.2M	1.2M	1.4M	770.9K
Common Stock	1.1M	1.2M	1.2M	1.2M	1.3M	801.6K
Net Tangible Assets	1.4B	1.0B	588.2M	(158.2M)	(182.0M)	(172.9M)
Retained Earnings Total Equity	(3.7B)	(4.6B)	(5.4B)	(6.6B)	(5.9B)	(5.6B)
Capital Surpluse	5.2B	5.6B	6.1B	6.5B	7.4B	7.8B
Inventory	56.3M	92.3M	122.7M	129.0M	89.1M	93.6M
Non Current Liabilities Other	603.8M	1.6B	1.7B	1.5B	1.6B	1.7B

Alnylam Pharmaceuticals Investors Sentiment

The influence of Alnylam Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Alnylam. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.

Investor biases related to Alnylam Pharmaceuticals' public news can be used to forecast risks associated with an investment in Alnylam. The trend in average sentiment can be used to explain how an investor holding Alnylam can time the market purely based on public headlines and social activities around Alnylam Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.

Alnylam Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Alnylam Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Alnylam Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Alnylam Pharmaceuticals.

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Alnylam Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Alnylam Pharmaceuticals' short interest history, or implied volatility extrapolated from Alnylam Pharmaceuticals options trading.

Pair Trading with Alnylam Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alnylam Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alnylam Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Alnylam Stock

0.74	FHTX	Foghorn TherapeuticsInc Financial Report 13th of May 2024	Pair Corr
0.74	HCWB	HCW Biologics	Pair Corr
0.69	KRYS	Krystal Biotech Financial Report 13th of May 2024	Pair Corr
0.68	ELEV	Elevation Oncology Earnings Call This Week	Pair Corr
0.65	IOVA	Iovance Biotherapeutics Financial Report 14th of May 2024	Pair Corr

The ability to find closely correlated positions to Alnylam Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alnylam Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alnylam Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alnylam Pharmaceuticals to buy it.

The correlation of Alnylam Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alnylam Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alnylam Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Alnylam Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Alnylam Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alnylam Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alnylam Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alnylam Pharmaceuticals Stock:

How To Invest In Alnylam

Details

Is Alnylam Stock a good investment?

Details

What is Alnylam Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alnylam Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.

You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..

Complementary Tools for Alnylam Stock analysis

When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings
	Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges
	Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
	ETFs Find actively traded Exchange Traded Funds (ETF) from around the world
	Transaction History View history of all your transactions and understand their impact on performance

Is Alnylam Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alnylam Pharmaceuticals. If investors know Alnylam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alnylam Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(3.52)

Revenue Per Share

14.637

Quarterly Revenue Growth

0.312

Return On Assets

(0.05)

Return On Equity

(15.01)

The market value of Alnylam Pharmaceuticals is measured differently than its book value, which is the value of Alnylam that is recorded on the company's balance sheet. Investors also form their own opinion of Alnylam Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Alnylam Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alnylam Pharmaceuticals' market value can be influenced by many factors that don't directly affect Alnylam Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Alnylam Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alnylam Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alnylam Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Alnylam Net Invested Capital vs Short Long Term Debt Analysis

Net Invested Capital vs Short Long Term Debt

Net Invested Capital vs Short Long Term Debt Correlation Analysis

Correlation Coefficient

Net Invested Capital

Short Long Term Debt

Alnylam Pharmaceuticals fundamental ratios Correlations

Alnylam Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Alnylam Pharmaceuticals fundamental ratios Accounts

Alnylam Pharmaceuticals Investors Sentiment

Pair Trading with Alnylam Pharmaceuticals

Moving against Alnylam Stock

Complementary Tools for Alnylam Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 0.99	Total Assets
Total Liab	+ 0.99	Other Current Liab
Total Current Assets	+ 0.99	Cash And Short Term Investments
Total Liab	+ 0.99	Non Current Liabilities Total
Long Term Debt	+ 0.99	Non Current Liabilities Total
Cash And Short Term Investments	+ 0.98	Total Assets

Property Plant Equipment	- 0.98	Retained Earnings
Property Plant And Equipment Gross	- 0.98	Retained Earnings
Other Stockholder Equity	- 0.97	Retained Earnings
Retained Earnings	- 0.97	Other Current Liab
Retained Earnings	- 0.97	Total Assets
Total Current Assets	- 0.96	Retained Earnings